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SUMMARY
Background
In patients with cirrhosis, ascites is defined as refractory when it cannot
be mobilized or recurs early in standard diuretic therapy.
Aim
To compare the safety and efficacy of intravenous high-dose furosemide
+ hypertonic saline solutions (HSS) with repeated paracentesis in
patients with cirrhosis and refractory ascites.
Patients and methods
Eighty-four subjects (59 ⁄25 M ⁄F) with cirrhosis, mostly of viral aetiol-
ogy, admitted for refractory ascites, were randomly assigned to receive
furosemide (250–1000 mg ⁄bid i.v.) plus HSS (150 mL H2O with NaCl
1.4–4.6% or 239–187 mEq ⁄L) (60 patients, Group A) or to repeated
paracentesis and a standard diuretic schedule (24 patients, Group B).
Results
During hospitalization, Group A patients had more diuresis
(1605  131 mL vs. 532  124 mL than Group B patients; P < 0.001)
and a greater loss of weight at discharge ()8.8  4.8 kg vs. )4.5 
3.8 kg, P < 0.00). Control of ascites, pleural effusions and ⁄or leg
oedema was deemed significantly better in Group A.
Conclusions
This randomized pilot study suggests that HHS plus high-dose furose-
mide is a safe and effective alternative to repeated paracentesis when
treating hospitalized patients with cirrhosis and refractory ascites.
Larger studies will be needed to evaluate long-term outcomes such as
readmission and mortality.
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INTRODUCTION
According to the International Ascites Club,1 refrac-
tory ascites is defined by the lack of response to high
doses of diuretics (spironolactone 400 mg ⁄day and
furosemide 160 mg ⁄day) or the development of
adverse effects (hyperkalemia, hyponatremia, hepatic
encephalopathy or renal failure) that prohibit further
use of diuretics. Few studies have compared paracente-
sis and diuretics in the treatment of tense or refractory
ascites. Quintero et al.2 randomly assigned patients
with tense ascites to treatment with either paracentesis
plus intravenous albumin infusion or diuretics, show-
ing similar outcomes. Salerno et al.3 confirmed
that repeated paracentesis with human albumin
replacement was safe, effective and more rapid than
traditional diuretic therapy in treating tense ascites.
Paracentesis poses, however, a number of issues in
patient management and alternative treatments to
overcome the limitations of diuretic therapy and
repeated paracenteses are certainly needed.4, 5
Cirrhosis and congestive heart failure (CHF) are
major clinical disease states characterized by renal
sodium and water retention with oedema formation. In
these diseases, abnormalities of circulatory and volume
homeostasis elicit neuro-hormonal responses influenc-
ing renal function and leading to retention of sodium
and water.6 Furthermore, prior observations in human
subjects and in experimental animals with either
cirrhosis7–10 or CHF indicate that an increase in effer-
ent renal sympathetic nerve activity (ERSNA), which
served to antagonize the diuretic and natriuretic
effects of atrial natriuretic peptides, is present and
contributes to the renal sodium and water retention.
The model of refractory congestive heart failure, on
the basis of these similarities and taking into account
other pathophysiological differences between these two
syndromes, may be helpful when exploring possible
innovative treatments for refractory ascites in cirrhosis.
When diuretic resistance occurs in CHF, proposed
therapeutic options include higher doses of furosemide
or constant furosemide infusion.11 Several studies have
demonstrated the efficacy of hypertonic saline solution
(HSS) infusion when regional organ blood flow is
impaired.12 HSS was first applied in this way for the
primary treatment of severe haemorrhagic and
traumatic shock and this therapy promptly restored
central hemodynamics and peripheral blood flow.12
The suggested mechanisms were direct myocardial
stimulation with high cardiac output maintenance,12, 13
increase in intravascular volume,14 reduction in tissue
oedema (shifting of tissue water along the osmotic
gradient), increased renal blood flow and reduced
sympathetic tone.15 All of these mechanisms are
potentially relevant to the treatment of refractory
ascites in cirrhosis.
A few years ago, our group performed a randomized
study16 to evaluate the effects of the combination of
high-dose furosemide and small-volume HSS in the
treatment of refractory CHF. One hundred seven patients
with refractory CHF were randomized to receive an IV
infusion of furosemide (500–1000 mg) plus HSS
(150 mL of 1.4–4.6% NACl) in 30 min twice a day or
furosemide alone (500–1000 mg) twice a day over 6 to
12 days, on a normosodic diet. A significant increase in
daily diuresis and natriuresis was observed in both
groups, but it was more significant in the group receiv-
ing HSS, in which the serum Na level also increased.
High-dose furosemide plus HSS was effective and well-
tolerated, leading to improvement in the quality of life
measurements of CHF. It also reduced mortality after
discharge (survival 55% vs. 13% at 1 year).
On the basis of our former experience,16 we have
designed a study aiming to evaluate the safety and
efficacy of intravenous high-dose furosemide plus HSS
compared with repeated paracentesis and a standard
oral diuretic schedule, in patients with cirrhosis and
refractory ascites.
PATIENTS AND METHODS
All consecutive cirrhotic patients presenting between
January 2002 and December 2007 with refractory
ascites unresponsive to ambulatory treatment at Paler-
mo’s University Hospital (Azienda Ospedaliera Policli-
nico ‘Paolo Giaccone’) who were admitted to two Units
(Internal Medicine; Emergency Medicine) of the ‘Dipar-
timento Biomedico di Medicina Interna e Specialistica’
of University of Palermo were offered enrolment in
the study protocol after a diagnosis of refractory
ascites had been made and all potential contraindica-
tions excluded.
Refractory ascites was defined according to the
International Ascites Club criteria1 as either: (a) diure-
tic-resistant refractory ascites: <1.5 kg ⁄week weight
loss while being treated with furosemide (160 mg ⁄day)
and spironolactone (400 mg ⁄day) or an equivalent
dose of a loop-acting and distal-acting diuretic; or (b)
diuretic-intractable refractory ascites: <1.5 kg ⁄week
weight loss as a result of the inability to use an
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effective dose of diuretic because of development of
diuretic-induced hyponatremia (sodium level <125
mEq ⁄L), hyperkalemia (potassium level >5.5 mEq ⁄L),
renal failure (doubling of serum creatinine or values
>2.5 g ⁄dL) or encephalopathy; (c) previous dietary
restriction of sodium between 50 and 66 mEq ⁄day.
The ascites was considered symptomatic if it had
necessitated removal of at least 10 L of ascites in
the 2 months preceding randomization for relief of
symptoms.
The study was approved by the institutional Ethics
Committee and written informed consent was obtained
for all patients.
Exclusionary criteria were: inability to obtain
informed consent, possible noncirrhotic ascites,
congestive heart failure (defined by clinical exam and
echocardiogram), acute renal failure, hepatocellular
carcinoma [based on the Barcelona Clinic liver Cancer
(BCLC) criteria],13 complete portal vein thrombosis,
active sepsis or other incurable cancers.
Each patient was assessed daily from admission until
discharge with a complete objective examination,
assessment of ascites grade [evaluated by International
Ascites Club criteria1 defining three grades: grade I
ascites, fluid detected only by ultrasound; grade II,
moderate ascites with symmetrical distension of the
abdomen; grade III, large or tense ascites with marked
abdominal distension], assessment of Child-Pugh
score, measurement of blood pressure, heart rate,
diuresis and body weight, clinical assessment of
pleural effusion.
Blood samples were obtained every 3 days to deter-
mine serum electrolytes (sodium, potassium, chlorine),
albumin, uric acid, urea, creatinine, prothrombin
activity, activated partial thromboplastin time, fibrino-
gen, full blood counts, glucose and ammonia. Urine
samples were collected to determine sodium and
potassium excretion at admission and at discharge. All
patients underwent a chest X-ray at admission and at
discharge, a twelve derivation electrocardiogram at
admission, while an abdominal echo-tomography was
performed both at admission and at discharge to
quantify ascites.
Patients were randomly assigned by the use of
sequentially numbered boxes (prepared before starting
the study by a computerized, non-alternating
sequence) to the following groups:
(i) Group A: treatment with intravenous infusion of
furosemide (doses 250–1000 mg ⁄bid) plus small vol-
umes of HSS (150 mL 1.4–4.6% NaCl), from the first
day after admission until 3 days before discharge, with
water restriction and a normal sodium diet.
(ii) Group B: repeated paracentesis (4 to 6 L daily)
from the first day after admission until 3 days before
discharge with albumin reinfusion at a rate of 5 to
8 g ⁄L of removed ascites. The last paracentesis (at
3 days from admission) was a total paracentesis
(8.7  2.5 L) plus i.v. albumin infusion (8 g per litre
of ascitic fluid removed) following a method previ-
ously described.1 After last mobilization of ascites,
patients were assigned to receive diuretic therapy with
oral furosemide (increasing doses up to a maximum of
160 mg ⁄day) and oral spironolactone (400 mg ⁄day)
was given. Water restriction and a normal sodium diet
were given throughout the in-hospital stay.
Dosing of furosemide in Group A patients was gov-
erned by clinical parameters such as blood pressure
and severity of ascites, while the concentration of
hypertonic saline solution was calculated as a serum
sodium value according to the following criteria:
(i) For serum sodium £125 mEq ⁄L hypertonic sal-
ine solution at 4.6%. (787.2 mEq ⁄L NaCl).
(ii) For serum sodium between 126 and 135 mEq ⁄L
hypertonic saline solution at 3.5% (599 mEq ⁄L NaCl).
(iii) For serum sodium ‡136 mEq ⁄L hypertonic
saline solution between 1.4% and 2.4% (239.6–
410.74 mEq ⁄L NaCl).
Daily dosage of furosemide was reassessed according
to diuresis, blood pressure and potassium levels.
Efficacy endpoints were:
(i) reduction in body weight (D body weight) at
discharge;
(ii) relief of overt ascites at discharge 3 days after
the end of diuretic treatment period or after last para-
centesis (ascites graded at admission and at discharge
according to International Ascites Club criteria);
(iii) improvement in Child Pugh score at discharge;
(iv) improvement in any co-existing fluid overload
(leg oedema; pleural effusion) at discharge; (pleural
effusion was evaluated clinically and by chest X-ray
at discharge).
In Group A, achievement of these endpoints at
3 days from discharge determined the end of intrave-
nous therapy and switching to oral furosemide (range
200–500 mg ⁄die) and spironolactone (400 mg ⁄day),
while Group B continued therapy until discharge.
Safety endpoints were:
(i) new onset hepatic encephalopathy (HE);18
(ii) new onset spontaneous bacterial peritonitis
(SBP);
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(iii) acute renal failure in patients without renal
impairment at admission, diagnosed by a serum creati-
nine level increasing by more than 50% over the base-
line value or to above 1.5 mg ⁄dL;19
(iv) impairment of pre-existing renal failure in
patients with pre-existing renal impairment, diagnosed
by serum creatinine increasing by more than 50%
above baseline;19
(v) incidence of hepatorenal syndrome (HRS);19
(vi) incidence of gastrointestinal (GI) bleedings. Gas-
trointestinal bleeding refers to any bleeding that starts
in the gastrointestinal tract, i.e. from the mouth to the
large bowel:
(1) Upper GI bleeding: between the mouth and
outflow tract of the stomach; (2) Lower GI bleeding:
from the outflow tract of the stomach to the anus
(small and large bowel included).
Statistical analysis
Results are presented as means  s.d. Analyses of the
data were performed using the unpaired Student’s t
test and the nonparametric test of Mann–Whitney.
The chi-square test was used for comparing distribu-
tions and frequency of complications. All reported P
values less than 0.05 were considered statistically
significant.
To calculate the number of patients to be enrolled,
we defined as meaningful a significant difference in
detectable ascites frequency at discharge between the
two groups, with a beta error of 20% and a power of
0.80. To the estimated sample size of 80 patients (60
in Group A and 20 in Group B), we added four more
patients to compensate for possible drop outs; the final
sample, therefore, comprised 84 patients.
RESULTS
We recruited 108 subjects with refractory ascites (73
with diuretic-resistant refractory ascites and 35 with
diuretic-intractable refractory ascites). Twenty subjects
were excluded on the basis of exclusion criteria and
four patients refused to participate in the study.
Eighty-four patients (59 men and 25 women) (58 with
diuretic-resistant refractory ascites and 26 with diure-
tic-intractable refractory ascites) agreed to participate
in the study and were randomized: 60 were assigned
to Group A and 24 to Group B. The mean age was
64  13.6 years in Group A and 64.8  8.06 years in
Group B (see Table 1).
In Group A, 42 patients (70%) had Hepatitis C (HCV)
cirrhosis; four patients (6.6%) had Hepatitis B virus
(HBV) cirrhosis; two (3.3%) had combined HCV ⁄HBV
cirrhosis; 11 (18.3%) had alcohol cirrhosis without
viral infection and one patient had idiopathic cirrhosis.
In Group B, 14 patients (58.3%) had HCV cirrhosis;
three patients (12.5%) had HBV cirrhosis; five (20.8%)
had combined HCV ⁄HBV cirrhosis and two (8.3%) had
alcohol cirrhosis.
In Group B, the mean number of paracentesis
performed in the whole group was 2.7  0.95 (range
1–4), the mean volume of ascites removed was 4.4
(1.4) L.
At discharge, patients of Group A showed signifi-
cantly higher diuresis and sodium plasma levels and
significantly lower body weight and leg oedema and
pleural effusion prevalence and median Child Pugh
score; the median change in Child-Pugh score at dis-
charge was significantly higher in Group A compared
with Group B ()1.7 vs.)0.9; P < 0.05) (see Tables 2
and 3).
At discharge, 14 subjects (23.3%) in Group A had
ascites (detected clinically or by ultrasound) vs. 11
(45.8%) in Group B.
No other significant difference was observed in
terms of other laboratory and clinical variables
between the two groups (ammonium, potassium
plasma levels, new onset episodes of HE, incidence of
gastrointestinal bleeding, acute renal failure or
pre-existing renal failure progression, hepatorenal
syndrome). There was no difference in hospital mortal-
ity between the two groups (see Table 3).
In Group A, no significant difference was observed
between patients with the two subtypes of refractory
ascites, diuretic-resistant and diuretic-intractable asci-
tes.
DISCUSSION
Our pilot study showed how treatment with high-dose
furosemide plus small-volume of HSS is safe and more
effective compared with repeated paracentesis plus
diuretic treatment in subjects with refractory ascites.
At the time of discharge, patients in Group A dem-
onstrated significantly greater diuresis, higher plasma
sodium levels, lower body weight, less leg oedema and
smaller volume pleural effusion than Group B patients.
This could be because of a more stable maintenance of
volume reduction with high-dose diuretic treatment
compared with repeated paracentesis.
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Changes in body weight and urinary sodium deter-
minations reflect response to treatment and represent
a key outcome in patients with ascites. Our findings,
through the evaluation of body weight, provide a
direct outcome evaluation about the higher efficacy of
high-dose furosemide + HSS treatment compared with
repeated paracentesis.
Quintero et al.2 analysed 72 cirrhotics with tense
ascites randomly assigned to treatment with either
paracentesis plus intravenous albumin infusion or
diuretics and showed that paracentesis was not associ-
ated with significant changes in renal function. Gines
et al.26 showed how paracentesis was effective in elim-
inating the ascites and did not induce significant
changes in renal and hepatic function, plasma volume,
cardiac index, peripheral resistance and plasma renin
activity (plasma norepinephrine, antidiuretic hormone
concentration and urinary excretion of prostaglandin
E2 and 6-keto-prostaglandin F1a). They also reported
a significantly higher incidence of HE, renal impair-
ment and electrolyte disturbances occurring in patients
treated with diuretics. More recently, Salerno et al.28
compared the effects of large-volume paracentesis and
transjugular intrahepatic portosystemic shunt (TIPS) in
cirrhotic patients with refractory ascites and showed
that TIPS significantly improves ascites recurrence-free
survival of cirrhotic patients with refractory ascites,
although the cumulative probability of developing the
first episode of HE was similar between the groups.
However, there are some disadvantages in repeated
paracentesis. Ascitic fluid opsonic activity and ascitic
fluid C3 concentrations are important protective fac-
tors against spontaneous bacterial peritonitis. Ljubicic
et al.27 compared the effect of diuretic administration
alone vs. single large-volume therapeutic paracentesis
followed by administration of diuretics on ascitic fluid
opsonic activity on ascites and serum immunoglobulin
and complement concentrations in patients with alco-
holic cirrhosis and tense ascites. These authors showed
that the ascitic fluid opsonic activity increased signifi-
cantly in patients treated with diuretics alone, whereas
in the group of patients treated with therapeutic
Table 1. Demographic, clinical
and laboratory characteristics
of subjects with refractory
ascites
High-dose
furosemide + HSS
Seriate
paracentesis
Number of subjects 60 24
Gender (M ⁄ F) 39 ⁄ 21 14 ⁄ 10
Age (years) (mean  s.d.) 64.8  11.5 63. 9  9.2
Aetiology of cirrhosis n (%)
HBV 4 (6.6%) 3 (12.5%)
HCV 42 (70%) 14 (58.3%)
HCV ⁄HBV 2 (3.3%) 5 (20.8%)
Alcohol-related 11 (18.3%) 2 (8.3)
Diuretic-resistant refractory ascites, n (%) 41 (68.3) 17 (70.8)
Diuretic-intractable refractory ascites, n (%) 18 (30) 8 (33.3)
Pre-treatment diuretics
Furosemide, n (%) 60 (100) 24 (100)
Spironolactone, n (%) 60 (100) 24 (100)
Oesophageal varices (F1 ⁄ F2 ⁄ F3); n (%) 19 (31.6); 26
(43.3); 15 (25)
5 (20.8); 11
(45.8); 8 (33.3)
Bilirubin (mg ⁄ dL) (mean) 2.8  0.9 3.0  1
Albumin (g ⁄ L) (mean) 2.8  4 2.6  6
Prothrombin time (% of control) 41  14 47  17
INR 1.79  1.3 1.80  1.3
Sodium (mEq ⁄ L) (mean  s.d.) 133  1.4 134  1.7
Potassium (mEq ⁄ L) (mean  s.d.) 4.2  0.8 4.3  0.3
Diuresis (mL ⁄ 24 h) 325  147 412  198
Hospital deaths (n ⁄%) 2 (3.3) 1 (4.4)
Demographic and clinical data are expressed as number (percentage). Laboratory
variables are expressed as mean  s.d. HBV, hepatitis B virus; HCV, hepatitis C virus;
Pre-treatment drugs, drugs used immediately prior to hospitalization or study
enrolment.
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paracentesis followed by diuretics, the ascites opsonic
activity remained stable. In our patients, we observed
no case of SBP among those treated with high-dose
furosemide + HSS and two cases of SBP among
patients who underwent repeated paracentesis.
Cirrhotic patients with ascites refractory to diuretics
also have blunted response to marked elevation of
plasma atrial natriuretic factor levels alone or to mod-
erate intravascular volume expansion by head-out
water immersion. Wong et al.29 reported that massive
(as opposed to moderate) volume expansion or greatly
elevated levels of plasma atrial natriuretic factor
associated with moderate volume expansion can
improve blunted atrial natriuretic factor responsiveness
in cirrhotic patients with refractory ascites. Thus,
volume expansion could represent a way to improve
natriuretic response in patients with refractory ascites.
A recent study by our group30 showed that in patients
with refractory congestive heart failure, treatment with
HSS plus i.v. high-dose furosemide was associated
with a significant reduction in BNP levels, thus
suggesting possible use in refractory ascites. The
formation of ascites in cirrhosis is the final conse-
quence of a combination of abnormalities in the
splanchnic and systemic circulation as well as renal
function abnormalities that bring about the accumula-
tion of fluid in the peritoneal cavity (forward theory).
The pathophysiological basis of higher efficacy of
treatment with furosemide + HSS could be because of
both volume expansion and improved reduction in
sinusoidal portal pressure resulting in a fall in the
plasma renin activity and serum aldosterone levels, a
rise in renal blood flow and glomerular filtration rate
associated with improved natriuresis. This effect occurs
despite a possible exacerbation of the hyper-dynamic
circulation, with a further fall in systemic vascular
resistance and further increase in cardiac output. Nev-
ertheless, it is possible that in our patients treated with
furosemide + HSS, the HSS-related volume expansion
served to compensate the ‘underfilling’ mechanisms
that characterize ascitic cirrhosis. Small-volume HSS
clearly induces an increase in the extracellular
Table 2. Clinical and laboratory variables before (at admission) and after treatment with high-dose furosemide + HSS
(Group A) or after seriated paracentesis (Group B)
Furosemide
plus HSS (n: 60)
P
Seriated paracentesis
(n: 24)
PBefore After Before After
Number of subjects 60 60 24 24
Weight (kg) 78  5.6 70  7.4 <0.001 77  3.8 73.8  3.8 <0.001
Diuresis (mL ⁄ 24 h) 550  147 1805  131 <0.05 580  112 750  124 0.07
Serum creatinin (mg ⁄ dL) (mean ) 1.7  0.5 1.45  0.3 0.06 1.56  0.6 1.76  0.6 0.08
Uric acid (mg ⁄ dL) (mean  s.d.) 4.4  0.7 5.7  0.4 0.05 4.2  0.6 4.3  0.2 0.79
Sodium (mEq ⁄ L) (mean  s.d.) 133  1.4 137  3.8 0.88 134  1.7 133  4.6 0.73
Potassium (mEq ⁄ L) (mean  s.d.) 4.2  0.8 4.4  0.6 <0.001 4.3  0.3 4.2  0.5 0.04
Urinary Na (mEq ⁄ 24 h) 49.5  9.4 158  25 <0.05 47.8  18 54.5  12.4 0.70
Urinary K (mEq ⁄ 24 h) 56.3  7.6 83  21 <0.05 54.3  11.1 59  29 0.63
Ascites n (%) 60 (100) 14 (23.,3) <0.001 24 (100) 11 (45.8) <0.001
Grade I - 8 (13.3) <0.001 - -
Grade II 14(23.3) 3 (5) <0.001 5 (20.8) 9 (37.5) 0.032
Grade III 46(76.6) 3 (5) <0.001 19 (79.1) 2 (8.3) <0.001
Ammonium (mean  s.d.) (lg ⁄ dL) 37  7 38  9 0.58 34  7 34  2 0.28
Leg oedema (n ⁄%) 49 (81.6) 4 (6.6) <0.001 18 (75) 16 (66.6) 0.04
Pleural effusion (n ⁄%) 11(18.3) 2 (3.3) <0.001 5 (20.8) 4 (16.6) 0.07
Child Pugh score (median) 9.2 7.6 0.037 9.8 8.9 0.045
HE (n ⁄%) 9 (15) 8 (13.3%) 0.82 4 (16.6) 3 (12.5) 0.78
SBP (n ⁄%) - - - - 2 (8.3) 0.05
Demographic and clinical data are expressed as number (percentage). Laboratory variables are expressed as mean  s.d.
HE, hepatic encephalopathy; SBP, spontaneous bacterial peritonitis; ascites grade was evaluated by Ascites International
Club criteria.5
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circulating concentration of NaCl with consequent
increment in the osmotic pressure and in the plasmatic
volume determining the fast redistribution of fluid in
the vascular compartment with consequential increase
in renal plasmatic flow.12, 14, 17 Such fast expansion of
the extracellular volume is also the cause of the reduc-
tion in the peritubular oncotic pressure that in combi-
nation with the increment of the hydrostatic pressure
reduces the proximal reabsorption of the Na.14, 15 HSS
can determine an increase in the diuretic efficiency
because HSS expands the arterial circulating volume
and increases the distribution of the sodium after the
proximal nephron until the thin portion of the ascend-
ing branch of the Henle loop, determining an increase
in natriuresis.14, 15 Another mechanism involved in the
effectiveness of the HSS seems to be the restoration of
normal production of renal E2 prostaglandin with
restoration of the normal medullar tonicity usually
altered by the chronic assumption of furosemide.31, 32
Our findings emphasize the treatment with intravenous
high-dose furosemide plus small volumes of HSS as
effective and safe in patients with refractory ascites.
An interesting finding is a slight, but not statistically
significant, reduction in the creatinine levels (1.45 
0.3 mg ⁄dL vs. 1.7  0.5 mg ⁄dL) in Group A patients,
probably attributable to the benefits brought by this
combination therapy to the hemodynamic and
renal perfusion, but requiring ulterior evaluation in
Table 3. Comparison between
the two groups treated with
high-dose furosemide + HSS
(Group A) or with seriate para-
centesis. (Group B) regarding
clinical and laboratory vari-
ables at discharge
High-dose furosemide
+ HSS (n: 60)
Seriate paracentesis
(n: 24) P
D weight (kg) )8.8  4.8 )4.5  3.8 <0.001
Diuresis (mL ⁄ 24 h) 1805  131 750  124 <0.001
Serum creatinin (mg ⁄ dL)
(mean  s.d.)
1.45  0.3 1.76  0.6 0.08
Sodium (mEq ⁄ L) (mean  s.d.) 137  3.8 133  4.6 0.04
Potassium (mEq ⁄ L) (mean  s.d.) 4.4  0.6 4.2  0.5 0.78
Urinary Na (mEq ⁄ 24 h) 158  25 54.5  12.4 <0.001
Urinary K (mEq ⁄ 24 h) 83  21 59  29 <0.05
Ascites at discharge (n ⁄%) 14 (23.3) 11 (45.8) <0.001
Grade I* 8 (13.3) - <0.001
Grade II* 3 (5) 9 (37.5) <0.001
Grade III* 3 (5) 2 (8.3) 0.029
Leg oedema (n ⁄%) 4 (6.6) 16 (66.6) <0.001
Pleural effusion (n ⁄%) 2 (3.3) 4 (16.6) <0.001
Child Pugh score (median) 7.6 8.9 0.04
D Child Pugh score (median) )1.6 )0.9 <0.05
HE (n ⁄%) 8 (13.3) 3 (12.5) 0.67
SBP (n ⁄%) – 2 (8.3)
HRS (n ⁄%) 4 (8) 2 (8.3) 0.54
GI bleedings (n ⁄%) 3 (5.5) 1 (4.1) 0,07
pre-existing renal failure
progression (n ⁄%)
4 (8) 2 (8.3) 0.43
Acute renal failure (n ⁄%) 2 (4) 1 (4.1%) 0.47
Hospitalization (days) (n ⁄%) 9.4  2.2 9.9  2.0 0.68
Intrahospital deaths (n ⁄%) 2 (3.3) 1 (4.4) 0.06
Demographic and clinical data are expressed as number (percentage). Laboratory
variables are expressed as mean  s.d.
D weight: body weight difference (body weight at admission – body weight after
treatment with high-dose furosemide + HSS or seriate paracentesis); D Child Pugh
score: Child pugh score change (Child Pugh score at admission – Child Pugh score at
discharge).
* Ascites grade was evaluated by Ascites International Club criteria.5
HE, hepatic encephalopathy; SBP, spontaneous bacterial peritonitis; HRS, Hepathorenal
Syndrome; GI bleedings, Gastrointestinal bleedings; Ascites at discharge, grade of
ascites evaluated 3 days after end of diuretic treatment period or last paracentesis.
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prospective long-term studies. Nevertheless, although
statistically insignificant, a potentially important find-
ing of our study is that high-dose furosemide diuresis
may not be as injurious to the kidney as high volume
paracentesis and this finding contrasts with what has
been a longstanding belief.
In contrast to previous studies,20, 21, 22, 23–26 we did
not observe a higher rate of hepatic encephalopathy
(HE) in the group treated with high-dose furosemide. A
combined derangement of cellular osmolarity coupled
with cerebral hyperaemia can explain the development
of brain oedema in HE.33 It is possible that HSS infusion
may influence cellular osmolarity to avoid increased
incidence of HE in patients treated with high-dose furo-
semide, but future studies should evaluate this issue.
Our study showed that treatment with high-dose i.v
furosemide + small-volume of hypertonic saline
solutions is more effective compared with repeated
paracentesis to achieve relief of ascites in patients with
refractory ascites with a higher change of Child-Pugh
Score and no significant differences between the two
group in new onset HE frequency.
This is a pilot study conducted on consecutive
patients with refractory ascites. Further studies are
needed to confirm our findings and to evaluate hemo-
dynamic and neurohormonal changes after treatment
with high-dose furosemide + small-volume HSS and
the possible relationship between these changes
and therapeutic effectiveness of this type of treatment.
Further studies are needed to test the effectiveness of
this treatment protocol on a longer-term follow-up
evaluation.
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